Phosphatidylserine (PS) and Stage IV Cancer: Latest Research 2026

By Insight Swarm Research Team, Medical Advisor: Nikhil Joshi, MD, FRCPC

Phosphatidylserine (PS) and Stage IV Cancer: Latest Research 2026

This page summarizes the current state of scientific research on Phosphatidylserine (PS) in the context of Stage IV Cancer as of 2026. The field evolves rapidly — this is a research summary, not medical advice. Consult your oncologist for personalized guidance.

Compound Overview

Phosphatidylserine (PS) (Phospholipid / Cognitive) — Dietary supplement; FDA qualified health claim for cognitive decline

Mechanism of action: Brain cell membrane component; HPA axis cortisol modulation; acetylcholine synthesis support; neuronal repair

Current evidence level: Multiple RCTs in older adults for cognitive decline; FDA qualified health claim (soy-derived)

2026 Research Landscape

Direct research on Phosphatidylserine (PS) specifically for Stage IV Cancer remains limited as of 2026, though the mechanistic connections continue to be explored in laboratory settings.

Key areas researchers are currently examining include:

  • Mechanistic studies: Understanding precisely how Phosphatidylserine (PS) affects the biological pathways involved in Stage IV Cancer progression
  • Safety characterization: Defining appropriate doses and monitoring protocols if clinical use is considered
  • Biomarker identification: Finding measurable indicators that could predict which patients might respond
  • Screening studies: Preclinical models are still being used to establish whether clinical investigation is warranted

Where to Find the Most Current Research

To access the latest peer-reviewed publications:

  • PubMed: Search "(Phosphatidylserine (PS)[tiab]) AND (Stage IV Cancer[tiab])" at pubmed.ncbi.nlm.nih.gov
  • ClinicalTrials.gov: Search for active and completed trials with Phosphatidylserine (PS) keywords
  • Google Scholar: Sort by date for most recent publications

Research Gaps

The most significant gaps in the Phosphatidylserine (PS) + Stage IV Cancer research landscape as of 2026 include: lack of large Phase III randomized trials, limited long-term safety data in Stage IV Cancer patients, and absence of biomarker-selected patient populations who might benefit most.

Medical Disclaimer: This page summarizes published research and is not medical advice. Never start, stop, or change any treatment based on information found online. Always consult qualified healthcare professionals before making treatment decisions.

Get a personalized AI-generated research report at insightswarm.ai.

Frequently Asked Questions

What are the most recent studies on Phosphatidylserine (PS) for Stage IV Cancer?

The most current peer-reviewed studies can be found on PubMed (pubmed.ncbi.nlm.nih.gov). Search for 'Phosphatidylserine (PS) Stage IV Cancer' filtered to the last 2 years. The current evidence level is: Multiple RCTs in older adults for cognitive decline; FDA qualified health claim (soy-derived).

Are there any 2025-2026 clinical trials for Phosphatidylserine (PS) in Stage IV Cancer?

Check ClinicalTrials.gov with 'Phosphatidylserine (PS)' as intervention and 'Stage IV Cancer' as condition. Filter by 'Recruiting' status for currently enrolling trials. Your oncologist can advise whether any trials may be appropriate for your specific situation.

Has the evidence for Phosphatidylserine (PS) in Stage IV Cancer changed recently?

The field evolves rapidly. The current evidence classification is: Multiple RCTs in older adults for cognitive decline; FDA qualified health claim (soy-derived). For the most up-to-date summary, Insight Swarm generates personalized research reports that incorporate the latest publications specific to your case.